Astria Therapeutics
Catabasis Pharmaceuticals discovers and develops innovative drugs for treating inflammatory conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $125m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | (68 %) | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (1687 %) | (5973 %) | (5636 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (1329 %) | (5067 %) | (4628 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Astria Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for allergic and immunological diseases.
The company's lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe and recurrent episodes of swelling.
Astria is also developing other preclinical programs for the treatment of allergic and immunologic diseases. The company's business model is based on developing and commercializing its product candidates, either on its own or in collaboration with other pharmaceutical companies. Astria's target market is the global market for HAE and other allergic and immunologic diseases, which is estimated to be worth billions of dollars.
Keywords: Biopharmaceutical, Allergic Diseases, Immunological Diseases, Hereditary Angioedema, Monoclonal Antibody, Plasma Kallikrein, Clinical Trials, Drug Development, Therapeutics, Healthcare
Tech stack
Investments by Astria Therapeutics
Edit